Navitoclax(CAS: 923564-51-6)

Navitoclax is a crystalline compound with a molecular weight of approximately 435.34 g/mol. It has a solubility of about 20 mg/mL in DMSO and is poorly soluble in water. Navitoclax is a potent inhibitor of BCL-2 family proteins, which makes it reactive towards these targets. It is stable under normal laboratory conditions but requires careful handling to maintain its activity.

Navitoclax is typically synthesized through a multi-step organic synthesis route. The key steps involve the protection of the hydroxyl groups, formation of the amide bond, and subsequent deprotection. Common catalysts used include TBTU and HATU, and the synthetic method is highly selective, yielding around 80-85% purity. The process is optimized for efficiency and scalability.

Navitoclax is primarily used in the pharmaceutical industry, particularly in cancer research and treatment. It has shown promise in clinical trials for the treatment of various hematological malignancies. Additionally, it has potential applications in the development of new drug candidates and as a tool compound in biological and chemical research.

When handling Navitoclax, it is essential to use appropriate personal protective equipment (PPE) such as gloves and a lab coat. Work should be conducted in a well-ventilated fume hood to minimize exposure. Spills should be cleaned up immediately with appropriate materials, and the Material Safety Data Sheet (MSDS) should be consulted for detailed safety information. Navitoclax is not a highly hazardous substance, but it should be handled with care to avoid skin contact and inhalation of dust.